NCT03206047 - Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

November 10, 2020

Study Completion Date

November 10, 2020

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

DRUG

Atezolizumab

Given IV

BIOLOGICAL

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Given SC

DRUG

Guadecitabine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Poly ICLC

Given SC

Trial Locations (17)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10065

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

43210

Ohio State University Comprehensive Cancer Center, Columbus

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

University of Chicago Medicine-Orland Park, Orland Park

60637

University of Chicago Comprehensive Cancer Center, Chicago

66205

University of Kansas Clinical Research Center, Fairway

68118

Nebraska Medicine-Village Pointe, Omaha

68198

University of Nebraska Medical Center, Omaha

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85719

Banner University Medical Center - Tucson, Tucson

University of Arizona Cancer Center-North Campus, Tucson

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH